Supporting Information

Total synthesis and absolute configuration reassignment of mollenines

A and B

Ming-Zhong Wang,*,a,b Tong-Xu Si,a Chuen-Fai Ku,b Xiao-Wan Li,a Zheng-Ming Li,c Hong-Jie Zhang,*,b and Albert S. C. Chan*,a

^aSchool of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, People's Republic of China

^bSchool of Chinese Medicine, Hong Kong Baptist University, 7 Baptist University Road, Kowloon Tong, Hong Kong SAR, People's Republic of China

^cState Key Laboratory of Elemento-organic Chemistry, Research Institute of Elemento-organic Chemistry, Nankai University, Tianjin 300071, People's Republic of China

Table of Contents

General Experimental S2 Preparation and Analytical Data of Compounds 1, 3, 4, 7, 8, 18-20, 22-25, and 29-31 S3 Reference S15 ¹H and ¹³C NMR Spectra S16

General Experimental

General information. Unless otherwise noted, commercially available reagents were used without further purification. All reactions were conducted in oven-dried or flame-dried glassware under a N₂ atmosphere, and at ambient temperature unless otherwise stated. All solvents were distilled prior to use: Benzene, THF, and toluene were distilled from Na/benzophenone, DMF, DCM, and triethylamine were distilled from CaH₂. All non-aqueous reactions were performed under an atmosphere of argon or nitrogen using oven-dried glassware and standard syringe in septa techniques. Concentration and evaporation under reduced pressure were performed at 10 - 400 mbar. Melting points were measured with a Stanford research system (OptiMelt-100). ¹H NMR spectra were recorded in CDCl₃ (unless stated otherwise) on a Bruker Avance 400 at 400 MHz (13C NMR spectra at 100 MHz). Chemical shifts are reported as δ values referenced to either a tetramethylsilane internal standard. Data for ¹H NMR are reported as follows: chemical shift (ppm), multiplicity (s = singlet, brs = broad singlet, d = doublet, t = triplet, q = quartet, m = multiplet), integration, coupling constant (Hz). Mass spectra were measured on an ABI Q-star Elite. The reaction progress was checked on pre-coated TLC plates. TLC was carried out using pre-coated sheets (Qingdao silica gel 60-G254, 0.2mm) which, after development, were visualized under UV light at 254 nm. Flash column chromatography was performed using the indicated

solvents on Qingdao silica gel 60 (200-300 mesh ASTM). Yields refer to chromatographically purified compounds, unless otherwise stated.

(2R,3aR,8aR)-1,8-Di-tert-butyl 2-methyl 3a-bromo-3,3a-dihydropyrrolo[2,3-b]indole-1,2,8(2H,8aH)-tricarboxylate (7). Method a: N-Bromosuccinimide (106.0 mg, 0.6 mmol) and AIBN (33.0 mg, 0.2 mmol) were added to a degassed solution of hexahydropyrroloindole 8¹ (240.0 mg, 0.57 mmol) in carbon tetrachloride (50.0 mL), and the reaction mixture was heated to reflux. After 1 hour, the reaction mixture was allowed to cool to room temperature. The volatiles were removed under reduced pressure and the residue was purified by column chromatography (EtOAc: hexanes = 1:14) to afford 7 (50.0 mg, 18%) as a colorless oil.

Method b: NaBr aqueous solution (2.0 g, in 10 mL water) was added to a solution of cyclopropylazetoindoline **17**¹ (1.8 g, 4.0 mmol) in THF (20.0 mL) at 0 °C. The reaction mixture was allowed to warm up to 25 °C within 1 hour and stirred for 10 hours. Volatiles were removed in *vacuo*, the residue was extracted with CH₂Cl₂/H₂O (100.0 mL, 1:1). The organic phase was concentrated in vacuum. The residue was purified by flash chromatography (EtOAc: hexanes = 1:14) to produce **7** (2.0 g, 95% yield) as a colorless oil. [α]_D²⁰ = -41.0 (c 1.4, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.56 (s, 1H), 7.28 (dd, J = 7.6, 3.6 Hz, 2H), 7.05 (t, J = 7.6 Hz, 1H), 6.45 (s, 1H), 4.54 (d, J = 8.4 Hz, 1H), 3.28 (d, J = 13.2 Hz, 1H), 3.18 – 3.02 (m, 1H), 3.13 (s, 3H) 1.60 (s, 9H), 1.47 (s, 9H); ¹³C NMR (100 MHz, CDCl₃)

δ 170.7, 152.1, 142.5, 132.5, 130.6, 123.9, 118.1, 84.3, 82.1, 81.2, 60.3, 59.6, 52.0, 43.1, 28.3, 28.2; HRESIMS *m/z* 519.1093 [M+Na]⁺, calcd for C₂₂H₂₉BrN₂O₆Na, 519.1101.

(2R,3aS,8aR)-1,8-Di-tert-butyl 2-methyl 3a-allyl-3,3a-dihydropyrrolo[2,3-b]indole-1,2,8(2H,8aH)-tricarboxylate (18). Method a: Allylzinc (II) bromide² (20.0 mL, 3.0 mmol, 0.15 M in THF) was added to a solution of cyclopropylazetoindoline 17 (1.0 g, 2.4 mmol) in THF (20.0 mL) at -30 °C. The reaction mixture was allowed to warm up to 0 °C within 1 hour and quenched with ice water (20.0 mL). Volatiles were removed in vacuum, the residue was extracted with CH₂Cl₂ (50.0 mL). The organic phase was concentrated in vacuum. The residue was purified by column chromatography (EtOAc: hexanes = 1:15) to produce 18 (0.16 g, 15% yield) and 7 (0.12 g, 10% yield) as colorless oil.

Method b: Allyltributyltin (1.5 g, 4.5 mmol) and AIBN (118 mg, 0.72 mmol) were added to a degassed solution of **7** (1.8 g, 3.6 mmol) in toluene (60.0 mL), and the mixture was heated at 90 0 C for 10 hours, and then cooled to room temperature. The volatiles were removed under reduced pressure and the residue was purified by column chromatography (EtOAc: hexanes = 1:10) to afford **18** (1.4 g, 85%). [α]_D²⁰ = -20.0 (c 0.7, CH₂Cl₂); 1 H NMR (400 MHz, CDCl₃) δ 7.52 (s, 1H), 7.23 – 7.14 (m, 1H), 7.04 (d, J = 6.7 Hz, 1H), 6.99 – 6.91 (m, 1H), 6.03 (s, 1H), 5.54 (td, J = 17.2, 7.6 Hz, 1H), 5.02 (t, J = 12.0 Hz, 2H), 4.54 (d, J = 8.8 Hz, 1H), 3.09 (d, J = 17.2)

Hz, 3H), 2.61 (d, J = 12.0 Hz, 1H), 2.45 – 2.30 (m, 3H), 1.56 (s, 9H), 1.46 (s, 9H); 13 C NMR (100 MHz, CDCl₃) δ 171.8, 152.3, 143.2, 134.2, 132.5, 128.4, 123.1, 122.9, 118.9, 117.4, 81.1, 80.5, 59.5, 55.5, 51.7, 42.2, 38.3, 28.2; HR-ESIMS m/z: calculated for C₂₅H₃₄N₂O₆Na [M+Na]⁺: 481.2314, found 481.2309.

(2R,3aS,8aR)-1,8-Di-tert-butyl 2-((R)-1-methoxy-4-methyl-1-oxopentan-2-yl) 3a-allyl-3,3a-dihydropyrrolo[2,3-b]indole-1,2,8(2H,8aH)tricarboxylate (4).

To a solution of **18** (1.3 g, 2.8 mmoL) in a mixture solvent of CH₃OH and THF (40 mL, 1:1), LiOH (0.5 g, 20.0 mmoL, dissolved in 20 mL water) was added at 0 °C. The mixture was stirred for 12 hours at 25 °C. Removal the organic solvent under vacuum, the residue was extracted with H₂O/CH₂Cl₂ (200 mL, 1:1). The aqueous layer was acidified with NaHSO₄ (pH < 3) and extracted with EtOAc (50.0 mL x 3). The organic layer were combined and concentrated to give **5** (1.2 g, 95%) as a colorless foam, which was used directly in the next step without purification.

A solution of **5** (1.0 g, 2.2 mmol), N, N-diisopropylethylamine (0.52 g, 4.0 mmol), and 2,4,6-trichlorobenzoyl chloride (0.73 g, 3.0 mmol) in dry THF (50.0 mL) were stirred for 1 hour at 0 °C. DMAP (60.0 mg, 0.5 mmol) and (*R*)-methyl 2-hydroxy-4-methylpentanoate (**6**, 0.32 g, 2.2 mmol) were dissolved in dry THF (10.0 mL) and added to the above reaction. The mixture was stirred at 25 °C for 10 hours, and then concentrated in vacuum.

The resulting mixture was extracted with EtOAc and water (200.0 mL, 1:1). After separation, the organic phase was concentrated in vacuum. The residue was purified by column chromatography (EtOAc: hexanes = 1:10) to afford **4** (0.81 g, 65%) as a colorless oil. $[\alpha]_D^{20} = -25.6$ (c 6, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.55 (brs, 1H), 7.23 – 7.15 (m, 1H), 7.06 (t, J = 9.2 Hz, 1H), 6.99 – 6.90 (m, 1H), 6.05 (s, 1H), 5.56 (td, J = 17.2, 7.6 Hz, 1H), 5.18 – 4.94 (m, 2H), 4.60 (t, J = 7.6 Hz, 1H), 4.46 – 4.40 (m, 1H), 3.65 (s, 3H), 2.70 (dd, J = 17.2, 9.2 Hz, 1H), 2.50 – 2.36 (m, 3H), 1.57 (brs, 9H), 1.57 – 1.47 (m, 3H), 1.47 (brs, 9H), 0.86 (d, J = 6.4 Hz, 3H), 0.83 (d, J = 6.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 176.0, 170.6, 152.3, 142.8, 132.5, 128.4, 123.6, 122.9, 119.0, 117.0, 81.2, 80.6, 71.4, 69.1, 59.4, 51.8, 42.4, 39.7, 28.2, 24.2, 22.8, 22.3; HRESIMS m/z 595.2995 [M+Na]⁺, calcd for C₃₁H₄₄N₂O₈Na, 595.2990.

(2R,3aS,8aR)-(R)-1-Methoxy-4-methyl-1-oxopentan-2-yl 3a-allyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole-2-carboxylate (19). To a solution of 4 (0.5 g, 0.87 mmol) in CH₂Cl₂ (20.0 mL) was added DIPEA (0.66 mL, 4.0 mmol) at 0 °C, followed by dropwise addition of TMSOTf (0.36 mL, 2.0 mmol) at 0 °C, stirred for 20 min. The cooling bath was removed and the mixture was stirred at room temperature for 12 hours. The reaction was quenched by addition of ice water (50.0 mL). Layers were separated, and the aqueous phase was extracted with CH₂Cl₂ (50.0 mL). The combined organic layers were concentrated in vacuum. The residue

was purified by flash chromatography (EtOAc: Hexane = 1:5) to produce the **19** (0.29 g, 90%) as a colorless oil. [α]_D²⁰ = -20.5 (c 1, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.10 – 6.97 (m, 2H), 6.71 (t, J = 7.6 Hz, 1H), 6.54 (d, J = 7.6 Hz, 1H), 5.83 – 5.56 (m, 1H), 5.18 – 5.01 (m, 2H), 4.87 (s, 1H), 4.83 (dd, J = 8.4, 4.4 Hz, 1H), 3.98 (dd, J = 7.6, 4.4 Hz, 1H), 3.64 (s, 3H), 2.57 – 2.38 (m, 4H), 1.73 – 1.53 (m, 3H), 0.91 (d, J = 6.4 Hz, 3H), 0.88 (d, J = 6.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 173.0, 170.8, 148.9, 134.1, 133.4, 128.1, 123.9, 119.1, 118.1, 109.6, 82.8, 71.2, 59.4, 57.2, 52.1, 43.0, 41.6, 39.8, 24.4, 22.8, 21.7; HRESIMS m/z 373.2125 [M+H]⁺, calcd for C₂₁H₂₉N₂O₄, 373.2122.

(2R,3aS,8aR)-Methyl 3a-allyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole-2-carboxylate (20). Iodotrimethylsilane (1.0 mL, 7.0 mmol) was added dropwise to a solution of **18** (1.0 g, 2.2 mmol) in acetonitrile (40.0 mL) at 0 °C. The resulting yellow solution was stirred at 0 °C. When starting material was consumed, which was monitored by TLC. N,N-Diisopropylethylamine (1.6 mL, 10.0 mmol) was introduced via a syringe at 0 °C. The cooling bath was removed and the reaction mixture was stirred for 20 min. Volatiles were removed in vacuum, and ice water (50.0 mL) was added to the residue. The aqueous solution was then extracted with EtOAc (50.0 mL x 3). The combined organic layers were concentrated in vacuum. The residue was purified by flash chromatography (EtOAc: Hexane = 1:1) to give **20** (0.51 g, 90%) as a colorless oil. $[\alpha]_D^{20} = -88.0$ (c

1, CH_2Cl_2); ¹H NMR (400 MHz, $CDCl_3$) δ 7.04 (dd, J = 20.0, 15.2 Hz, 2H), 6.70 (t, J = 7.6 Hz, 1H), 6.55 (d, J = 8.0 Hz, 1H), 5.71 (td, J = 15.2, 7.6 Hz, 1H), 5.13 - 5.01 (m, 2H), 4.85 (s, 1H), 3.88 (dd, J = 7.6, 3.2 Hz, 1H), 3.33(s, 3H), 2.55 - 2.31 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 174.3, 149.6, 134.1, 132.8, 128.2, 123.8, 118.7, 118.1, 109.4, 82.3, 59.9, 57.0, 51.8, 42.8, 41.4. HRESIMS m/z 259.1433 [M+H]⁺, calcd for C₁₅H₁₉N₂O₂, 259.1441. (2R,3aS,8aS)-Methyl 3a-allyl-1-((R)-2-hydroxy-4-methylpentanoyl)-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole-2-carboxylate (22). 2,4,6-Collidine (0.65 mL, 5.0 mmol) was added to a solution of 21 (0.3 g, 2.2 mmol) and BOPCl (0.76 g, 3.0 mmol) in THF (30.0 mL) at 25 °C. The mixture was stirred for 10 hours at 25 °C, and 20 (0.5 g, 1.9 mmol) was added and stirred for 10 hours at 25 °C, and the reaction was then quenched by the addition of ice H₂O (50.0 mL). Removal of THF under vacuum, the aqueous residue was extracted with EtOAc (50.0 mL x 3). The combined organic layers were concentrated in vacuo. The residue was purified by column chromatography on silica gel (EtOAc: hexanes = 1:8) to give 22 (0.47 g, 67%) as a colorless oil. $[\alpha]_D^{20} = -86.6$ (c 0.9, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) main peaks of rotamers δ 7.07 – 6.97 (m, 2H), 6.69 (t, J = 7.6 Hz, 1H), 6.58 (d, J = 7.6 Hz, 1H), 5.71 (qd, J = 16.4, 7.6 Hz, 1H), 5.32 (s, 1H), 5.17 - 5.04 (m, 2H), 4.40 (t, J = 8.4 Hz, 1H), 4.26 (4.00) (dd, J = 8.4, 4.4 Hz, 1H), 3.17 (s, 3H), 2.80 (d, J = 13.2 Hz, 1H), 2.53 – 2.43 (m, 2H), 1.97 - 1.85 (m, 1H), 1.70 - 1.58 (1.55-1.51) (m, 2H), 1.28 - 1.18

(1.08 - 1.02) (m, 1H), 0.99 - 0.88 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) main peaks of rotamers δ 175.7, 170.6, 149.8, 132.9, 129.4, 129.0, 123.8, 118.9, 118.6, 109.2, 81.4, 67.9, 59.2, 52.7, 43.2, 41.9, 39.5, 24.4, 23.5, 23.2, 21.4; HRESIMS m/z 373.2126 [M+H]⁺, calcd for C₂₁H₂₉N₂O₄, 373.2122. (3R,5aS,10bS,11aR)-10b-Allyl-3-isobutyl-5a,6,11,11a-tetrahydro-[1,4]oxazino[4',3':1,5]pyrrolo[2,3-b]indole-1,4(3H,10bH)-dione *(3)*. PTSA (0.17 g, 1.0 mmol) was added to a solution of **22** (0.4 g, 1.0 mmol) in toluene (20.0 mL). The mixture was heated and stirred for 20 min at 110 ⁰C, cooled, and quenched by the addition of saturated aqueous NaHCO₃ (50.0 mL). The aqueous residue was extracted with EtOAc (50.0 mL x 3). The combined organic layers were concentrated in vacuum. The residue was purified by column chromatography on silica gel (EtOAc: hexanes = 1:19) to give **3** (180.0 mg, 52%) as a colorless oil. $[\alpha]_D^{20} = -131.0$ (c 1, CH_2Cl_2); ¹H NMR (400 MHz, CDCl₃) δ 7.09 (dd, J = 15.2, 7.6 Hz, 2H), 6.78 (t, J = 7.6 Hz, 1H), 6.59 (d, J = 7.6 Hz, 1H), 5.71 (tt, J = 15.2, 7.6 Hz, 1H), 5.45 (s, 1H), 5.20 - 5.12 (m, 2H), 4.75 (dd, J = 9.6, 2.4 Hz, 1H), 4.42(t, J = 8.0 Hz, 1H), 2.70 (dd, J = 9.6, 7.6 Hz, 1H), 2.64 - 2.42 (m, 3H), 1.98-1.85 (m, 2H), 1.83 - 1.69 (m, 1H), 0.96 (d, J = 5.6 Hz, 3H), 0.93 (d, J =5.6 Hz, 3H); 13 C NMR (100 MHz, CDCl₃) δ 168.4, 166.8, 147.2, 132.7, 131.2, 128.8, 123.2, 119.6, 119.5, 109.8, 81.1, 77.2, 56.9, 55.5, 41.3, 38.2, 37.6, 23.9, 23.2, 21.3; HRESIMS m/z 341.1861 [M+H]⁺, calcd for C₂₀H₂₅N₂O₃, 341.1860.

(3R,5aS,10bS,11aR)-3-Isobutyl-10b-(3-methylbut-2-en-1-yl)-5a,6,11,11atetrahydro-[1,4]oxazino[4',3':1,5]pyrrolo[2,3-b]indole-1,4(3H,10bH)dione (1). To a 25 mL flame-dried flask was added diketomorpholine 3 (160 mg, 0.47 mmol), Hoveyda-Grubbs II catalyst (32.0 mg, 0.05 mmol) was added, followed by 2-methyl-2-butene (4.0 mL) and CH₂Cl₂ (15.0 mL). The flask was equipped with a condenser and heated to 38 °C for 10 hours. The reaction mixture was filtered through a silica gel plug, eluting with 50% EtOAc in hexanes. The filtrate was concentrated in vacuo. The residue was purified by column chromatography on silica gel (CH_2Cl_2 : hexanes = 1:3) to afford **1** (107 mg, 62%) as a colorless oil. $[\alpha]_D^{20} = -123.5$ (c 1.4, CH₂Cl₂); ¹H NMR (500 MHz, CDCl₃) δ 7.08 (dt, J = 13.5, 7.0 Hz, 2H), 6.77 (t, J = 7.0 Hz, 1H), 6.59 (d, J = 7.5 Hz, 1H), 5.38 (s, 1H), 5.30 (s, 1H), 5.12 (t, J = 7.5 Hz, 1H), 5.30 (s, 1H), 5.12 (t, J = 7.5 Hz, 1H), 5.38 (s, 1H), 5.30 (s, 1H), 5.12 (t, J = 7.5 Hz, 1H), 5.38 (s, 1H), 5.30 (s, 1H), 5.12 (t, J = 7.5 Hz, 1H), 5.38 (s, 1H), 5.30 (s, 1H), 5.12 (t, J = 7.5 Hz, 1H), 5.38 (s, 1H), 5.30 (s, 1H), 5.12 (t, J = 7.5 Hz, 1H), 5.38 (s, 1H), 5.30 (s, 1H), 5.12 (t, J = 7.5 Hz, 1H), 5.38 (s, 1H), 5.30 (s, 1H), 5.12 (t, J = 7.5 Hz, 1H), 5.38 (s, 1H), 5.30 (s, 1H), 5.12 (t, J = 7.5 Hz, 1H), 5.38 (s, 1H), 5.30 (s, 1H), 5.12 (t, J = 7.5 Hz, 1H), 5.38 (s, 1H), 5. = 7.5 Hz, 1H, 4.74 (dd, J = 9.0, 2.0 Hz, 1H), 4.40 (t, J = 7.5 Hz, 1H), 2.69(dd, J = 13.5, 7.0 Hz, 1H), 2.58 (dd, J = 13.5, 8.5 Hz, 1H), 2.48 (dd, J = 13.5, 8.5 Hz, 1H)13.5, 8.5 Hz, 1H), 2.44 – 2.36 (m, 1H), 1.97 – 1.89 (m, 2H), 1.81 – 1.75 (m, 1H), 1.71 (s, 3H), 1.59 (s, 3H), 0.96 (d, J = 6.0 Hz, 3H), 0.92 (d, J = 6.0 Hz, 3H), 0.926.0 Hz, 3H); 13 C NMR (125 MHz, CDCl₃) δ 168.5, 166.8, 147.1, 136.1, 131.7, 128.7, 123.2, 119.5, 118.3, 109.7, 81.2, 77.2, 57.0, 56.2, 37.7, 37.6, 35.0, 26.0, 23.9, 23.2, 21.2, 18.1; HRESIMS m/z 369.2170 [M+H]⁺, calcd for $C_{22}H_{29}N_2O_3$, 369.2173.

(2S,3aS,8aR)-1,8-Di-tert-butyl 2-methyl 3a-allyl-3,3a-dihydropyrrolo[2,3-b]indole-1,2,8(2H,8aH)-tricarboxylate (23). Allyltributyltin (1.7 g, 5.0

mmol) and AIBN (130 mg, 0.8 mmol) were added to a degassed solution of **16** (2.0 g, 4.0 mmol) in toluene (50 mL), and the mixture was heated at 90 0 C for 10 hours, and the reaction was cooled to room temperature. The volatiles were removed under reduced pressure and the residue was purified by column chromatography (EtOAc: hexanes = 1:10) to afford **23** (1.5 g, 84%) as a colorless oil. [α]_D²⁰ = -59.6 (c 3, CH₂Cl₂); 1 H NMR (500 MHz, CDCl₃) δ 7.50 (brs, 1H), 7.23 (t, J = 7.0 Hz, 1H), 7.13 (d, J = 7.0 Hz, 1H), 7.06 (d, J = 6.5 Hz, 1H), 6.03 (s, 1H), 5.52 (d, J = 7.5 Hz, 1H), 5.02 (d, J = 16.5 Hz, 2H), 3.89 (dd, J = 16.5, 9.0 Hz, 1H), 3.72 (s, 3H), 2.55 (dd, J = 12.0, 6.0 Hz, 1H), 2.44 - 2.33 (m, 2H), 2.12 (t, J = 12.0 Hz, 1H), 1.56 (s, 9H), 1.40 (s, 9H); 13 C NMR (125 MHz, CDCl₃) δ 172.9, 152.3, 142.2, 134.7, 132.2, 128.4, 123.5, 122.7, 119.0, 81.3, 80.3, 59.3, 55.4, 52.0, 41.9, 37.7, 28.3; HRESIMS m/z 481.2316 [M+Na]⁺, calcd for C₂₅H₃₄N₂O₆Na, 481.2309.

(2S,3aS,8aR)-Methyl 3a-allyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole-2-carboxylate (24). Compounds 24 (colorless oil, 0.5 g, 90%) was prepared from 23 (1.0 g, 2.2 mmol) with iodotrimethylsilane (1.0 mL, 7.0 mmol) under the same procedure as for 20. $[\alpha]_D^{20} = -98.5$ (c 1.4, CH₂Cl₂); 1 H NMR (500 MHz, CDCl₃) δ 7.12 – 6.96 (m, 2H), 6.73 (t, J = 7.0 Hz, 1H), 6.56 (t, J = 10.5 Hz, 1H), 5.75 – 5.60 (m, 1H), 5.11 – 4.97 (m, 3H), 3.90 (brs, 2H), 3.76 – 3.72 (m, 1H), 3.69 (s, 3H), 2.60-2.50 (m, 1H), 2.49 – 2.35 (m, 2H), 2.08 – 1.97 (m, 1H); 13 C NMR (125 MHz, CDCl₃) δ 173.8, 150.0,

134.1, 132.2, 128.3, 123.6, 118.8, 118.3, 109.1, 82.0, 59.2, 58.1, 52.2, 44.1, 43.1; HRESIMS m/z 259.1436 [M+H]⁺, calcd for C₁₅H₁₉N₂O₂, 259.1441. (2S, 3aS, 8aS)-Methyl 3a-allyl-1-((R)-2-hydroxy-4-methylpentanoyl)-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole-2-carboxylate (25).Compounds 25 (colorless oil, 0.39 g, 68%) was prepared from 24 (0.4 g, 1.5 mmol) with (R)-2-hydroxy-4-methylpentanoic acid (21) (0.2 g, 1.5 mmol) under the same procedure as for 22. $[\alpha]_D^{20} = -60.8$ (c 1.2, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.09 (dd, J = 12.0, 4.0 Hz, 2H), 6.82 – 6.74 (m, 1H), 6.62 (d, J = 7.6 Hz, 1H), 5.74 - 5.60 (m, 1H), 5.27 (s, 1H), 5.09(t, J = 12.0 Hz, 2H), 4.11 - 4.03 (m, 1H), 3.89 (dd, J = 12.0, 6.0 Hz, 1H),3.74 (s, 3H), 2.60 (dd, J = 13.6, 6.4 Hz, 1H), 2.50 (dt, J = 13.6, 6.8 Hz, 2H), 2.23 (dd, J = 21.6, 9.6 Hz, 1H), 1.93 - 1.81 (m, 1H), 1.60-1.42 (m, 2H),0.94 (d, J = 2.4 Hz, 3H), 0.93 (d, J = 2.4 Hz, 3H); 13 C NMR (100 MHz, CDCl₃) δ 180.5, 171.4, 149.3, 133.3, 131.0, 128.8, 123.3, 119.2, 118.9, 109.2, 81.9, 69.7, 58.4, 57.8, 52.6, 43.8, 42.5, 42.5, 24.6, 23.4, 21.4; HRESIMS m/z 373.2120 [M+H]⁺, calcd for C₂₁H₂₉N₂O₄, 373.2122. (3S,5aS,10bS,11aS)-10b-Allyl-3-isobutyl-5a,6,11,11a-tetrahydro-[1,4]oxazino[4',3':1,5]pyrrolo[2,3-b]indole-1,4(3H,10bH)-dione *(29)*. 2,4,6-Collidine (6.5 mL, 5.0 mmol) was added to a solution of (S)-2hydroxy-4-methylpentanoic acid (27, 0.2 g, 1.5 mmol) and BOPCl (0.76 g, 3.0 mmol) in THF (30.0 mL) at 25 °C. The mixture was stirred for 10 hours at 25 °C, and 24 (0.4 g, 1.5 mmol) was added and stirred for another 10

hours at 25 °C, and then quenched by the addition of ice H₂O (50.0 mL). After removal of THF under vacuum, the aqueous residue was extracted with EtOAc (100.0 mL). The organic layers were concentrated in vacuo. The residue was used directly in the next step without purification. PTSA (0.25 g, 1.5 mmol) was added to a solution of above residue in toluene (20.0 mL). The mixture was stirred at 110 °C for 20 min, cooled, and quenched by the addition of saturated aqueous NaHCO₃ (50.0 mL). The aqueous residue was extracted with EtOAc (50.0 mL). The organic layers were concentrated in vacuum. The residue was purified by column chromatography on silica gel (EtOAc: hexanes = 1:15) to give 29 (0.18 g, 35%, 2 steps) as a colorless oil. $[\alpha]_D^{20} = -375$ (c 1.4, CH₂Cl₂); ¹H NMR (500 MHz, CDCl₃) δ 7.04 (t, J = 8.0 Hz, 2H), 6.73 (t, J = 7.5 Hz, 1H), 6.55 (d, J = 7.5 Hz, 1H, 5.72 - 5.58 (m, 1H), 5.26 (s, 1H), 5.05 (dd, J = 21.0, 11.5)Hz, 2H), 4.66 - 4.59 (m, 1H), 4.11 - 4.04 (m, 1H), 2.65 (dt, J = 15.5, 7.5Hz, 1H), 2.44 - 2.39 (m, 2H), 2.36 (dd, J = 19.0, 9.5 Hz, 1H), 1.92 - 1.82(m, 2H), 1.71 (dd, J = 19.0, 9.5 Hz, 1H), 0.91 (d, J = 6.0 Hz, 3H), 0.84 (d, J = 1.71 (dd, J = 1.J = 6.0 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 168.6, 166.0, 148.5, 132.5, 130.1, 129.1, 123.4, 119.5, 119.4, 109.7, 79.5, 77.5, 57.4, 55.3, 41.6, 38.4, 37.7, 24.0, 23.2, 21.2; HRESIMS m/z 341.1855 [M+H]⁺, calcd for $C_{20}H_{25}N_2O_3$, 341.1860.

(3S,5aS,10bS,11aS)-3-Isobutyl-10b-(3-methylbut-2-en-1-yl)-5a,6,11,11a-tetrahydro-[1,4]oxazino[4',3':1,5]pyrrolo[2,3-b]indole-1,4(3H,10bH)-

dione (30). Compounds 30 (colorless oil, 99.0 mg, 61%) was prepared from 29 (150 mg, 0.44 mmol) with 2-methyl-2-butene (3.0 mL) under the same procedure as for 1. $[\alpha]_D^{20} = -322$ (c 6, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.17 – 7.09 (m, 2H), 6.81 (td, J = 7.6, 0.8 Hz, 1H), 6.64 (dd, J = 5.6, 2.4 Hz, 1H), 5.31 (s, 1H), 5.17 (dd, J = 14.0, 6.8 Hz, 1H), 5.13 (s, 1H), 4.72 (dd, J = 9.6, 2.8 Hz, 1H), 4.21 – 4.11 (m, 1H), 2.72 (dt, J = 12.8, 6.4 Hz, 1H), 2.45 (dt, J = 12.8, 9.6 Hz, 3H), 2.02 – 1.93 (m, 2H), 1.82 (t, J = 9.6 Hz, 1H), 1.74 (s, 3H), 1.56 (s, 3H), 1.00 (d, J = 6.4 Hz, 3H), 0.94 (d, J = 6.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 168.7, 166.0, 148.4, 136.2, 130.8, 128.9, 123.2, 119.5, 118.0, 109.7, 79.4, 77.5, 57.5, 56.0, 37.8, 37.7, 35.0, 25.9, 24.0, 23.2, 21.2, 17.9; HRESIMS m/z 369.2175 [M+H]⁺, calcd for C₂₂H₂₉N₂O₃, 369.2173.


(3S,5aS,10bS,11aS)-3-Isobutyl-10b-(3-methylbut-2-en-1-yl)-1,4-dioxo-1,3,4,10b,11,11a-hexahydro-[1,4]oxazino[4',3':1,5]pyrrolo[2,3-b]indole-6(5aH)-carbaldehyde (31). To a solution of 30 (50.0 mg, 0.14 mmol) in dry THF (5.0 mL), formic acid (0.5 mL) was added and stirred for 10 hours. After removal of the solvent and excess formic acid under vacuum, saturated aqueous NaHCO₃ (20.0 mL) was added to the above residue. The aqueous residue was extracted with EtOAc (50.0 mL). The organic layer was concentrated in vacuum. The residue was purified by column chromatography on silica gel (EtOAc: hexanes = 1:10) to give 31 (44 mg, 82%) as a colorless oil. $[\alpha]_D^{20} = -250$ (c 1, CH₂Cl₂); ¹H NMR (500 MHz,


CDCl₃) δ 9.03 (s, 1H), 8.02 (d, J = 8.0 Hz, 1H), 7.32 (t, J = 7.5 Hz, 1H), 7.24 (d, J = 7.5 Hz, 1H), 7.17 (t, J = 7.5 Hz, 1H), 5.81 (s, 1H), 5.03 (t, J = 7.0 Hz, 1H), 4.80 – 4.73 (m, 1H), 4.18 (dd, J = 10.5, 6.5 Hz, 1H), 2.80 (dd, J = 13.5, 6.5 Hz, 1H), 2.52 – 2.36 (m, 3H), 2.01 – 1.88 (m, 2H), 1.81 (t, J = 10.5 Hz, 1H), 1.70 (s, 3H), 1.52 (s, 3H), 0.98 (d, J = 6.0 Hz, 3H), 0.92 (d, J = 6.0 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 168.0, 165.5, 161.7, 140.1, 137.4, 133.9, 129.4, 125.4, 123.1, 117.3, 116.9, 78.4, 77.4, 57.4, 54.9, 38.8, 37.6, 35.8, 25.9, 23.9, 23.2, 21.2, 18.0; HRESIMS m/z 397.2123 [M+H]⁺, calcd for C₂₃H₂₉N₂O₄, 397.2122.

Reference


- 1. V. R. Espejo, X. B. Li, and J. D. Rainier, J. Am. Chem. Soc., 2010, 132, 8282.
- E. Negishi, L. D. Boardman, H. Sawada, V. Bagheri, A. T. Stoll, J. M. Tour, and C. L. Rand, *J. Am. Chem. Soc.*, 1988, **110**, 5383.









HSQC spectrum of 7 (CDCl₃)




HMBC spectrum of 7 (CDCl₃)




NOESY spectrum of **7** (CDCl₃)




1H NMR and ^{13}C NMR spectrum of 8 (CDCl3)







1H NMR and ^{13}C NMR spectrum of $\boldsymbol{18}$ (CDCl3)




¹H NMR and ¹³C NMR spectrum of **4** (CDCl₃)







¹H NMR and ¹³C NMR spectrum of **19** (CDCl₃)




¹H NMR and ¹³C NMR spectrum of **20** (CDCl₃)




¹H NMR and ¹³C NMR spectrum of **22** (CDCl₃)




^{1}H NMR and ^{13}C NMR spectrum of 3 (CDCl₃)




¹H NMR and ¹³C NMR spectrum of **1** (CDCl₃)




1H NMR and ^{13}C NMR spectrum of $\boldsymbol{23}$ (CDCl₃)




¹H NMR and ¹³C NMR spectrum of **24** (CDCl₃)




¹H NMR and ¹³C NMR spectrum of **25** (CDCl₃)




¹H NMR and ¹³C NMR spectrum of **29** (CDCl₃)




¹H NMR and ¹³C NMR spectrum of **30** (CDCl₃)




¹H NMR and ¹³C NMR spectrum of **31**(CDCl₃)



¹H NMR spectrum of mollenine A (CDCl₃, provided) and **1** (CDCl₃)



¹H NMR spectrum of mollenine A (CDCl₃, provided) and **30** (CDCl₃)



¹³C NMR spectrum of mollenine A (CDCl₃, provided) and **30** (CDCl₃)

